Track topics on Twitter Track topics that are important to you
Public release - September 21, 2018
The sales breakdown table on page 3 of the half-year financial report published on September 17, 2018 included distribution errors by geographical area.
The corrected table and related comments corrections have been restated in the semi-annual financial report available on the company's website: corporate.virbac.com under the section Investors - Financial reports - 2018.
The company also amended the same corrections on the investors' presentation available on the site.
Virbac: NYSE Euronext - compartment B - ISIN code: FR0000031577/SYMBOL: VIRP
Corporate finance: +33 4 92 08 71 32 - email@example.com - corporate.virbac.com
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...